StockData
COSCIENS Biopharma Inc. logo

COSCIENS Biopharma Inc. (CSCIF) stock

CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026Score 1/30
$6.49+0.00 (0.00%)

Close on Oct 19, 2026Market cap $24.10MP/E –Yield –

COSCIENS Biopharma gross margin

Gross margin is gross profit as a percentage of revenue.

COSCIENS Biopharma's gross margin for the twelve months ending Mar 31, 2026 was 38.0%. For fiscal 2025 it was 35.3%, against 49.3% the year before. The highest annual figure on record is 100.0% in fiscal 2016.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202535.3%−14.0
FY2024Dec 31, 202449.3%+8.2
FY2023Dec 31, 202341.1%−17.6
FY2022Dec 31, 202258.7%−39.6
FY2021Dec 31, 202198.3%+61.7
FY2020Dec 31, 202036.6%+13.6
FY2019Dec 31, 201922.9%−69.2
FY2018Dec 31, 201892.2%−7.8
FY2017Dec 31, 2017100.0%+0.0
FY2016Dec 31, 2016100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2026Mar 31, 202642.0%+15.4
Q4 FY2025Dec 31, 202534.5%−27.2
Q3 FY2025Sep 30, 202541.9%−9.3
Q2 FY2025Jun 30, 202535.4%+0.4
Q1 FY2025Mar 31, 202526.6%−17.3
Q4 FY2024Dec 31, 202461.7%+49.5
Q3 FY2024Sep 30, 202451.1%+9.9
Q2 FY2024Jun 30, 202435.0%−22.2
Q1 FY2024Mar 31, 202443.9%−55.3
Q4 FY2023Dec 31, 202312.2%−36.0
Q3 FY2023Sep 30, 202341.2%−58.0
Q2 FY2023Jun 30, 202357.3%−37.5
Q1 FY2023Mar 31, 202399.2%+1.1
Q4 FY2022Dec 31, 202248.2%−48.8
Q3 FY2022Sep 30, 202299.2%+0.0
Q1 FY2022Mar 31, 202294.8%−3.5
Q4 FY2021Dec 31, 202198.1%+57.7
Q3 FY2021Sep 30, 202197.1%+22.8
Q2 FY2021Jun 30, 202199.2%+16.9
Q1 FY2021Mar 31, 202198.3%+77.3
Q4 FY2020Dec 31, 202040.4%+1657.1
Q3 FY2020Sep 30, 202074.2%−25.8
Q2 FY2020Jun 30, 202082.4%+34.4
Q1 FY2020Mar 31, 202020.9%+22.4
Q4 FY2019Dec 31, 2019-1616.7%−1642.2
Q3 FY2019Sep 30, 2019100.0%+117.3
Q2 FY2019Jun 30, 201947.9%–
Q4 FY2018Dec 31, 2018-1.5%–
Q3 FY2018Sep 30, 201825.5%–
Q2 FY2018Jun 30, 2018-17.3%–

More COSCIENS Biopharma figures

See a number that looks wrong?